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Abstract: About half of all human tumors contain an inactivating mutation of p53, while in the remaining tumors, the p53 pathway is 
frequently abrogated by alterations of other components of its signaling pathway. In humans, the p53 tumor suppressor is part of a small 
gene family that includes two other members, p73 and p63, structurally and functionally related to p53. Accumulating evidences indicate 
that all p53-family proteins function as molecular hubs of a highly interconnected signaling network that coordinates cell proliferation, 
differentiation and death in response to physiological inputs and oncogenic stress. Therefore, not only the p53-pathway but the entire 
“p53-family pathway” is a primary target for cancer drug development. In particular, the p53-related protein p73 has a crucial role in de-
termining cellular responses to chemotherapy, and can vicariate p53 functions in triggering cell death after DNA damage in multiple ex-
perimental models. The biology and regulation of p73 is complex, since the TP73 gene incorporates both tumor-suppressive and proto-
oncogenic functions. However, the p73 gene is rarely mutated in tumors, so appropriate pharmacological manipulation of the p73 path-
way is a very promising approach for cancer therapy. Here we provide an overview of the principal mechanism of p73 regulation, and de-
scribe several examples of pharmacological tools that can induce p73 accumulation and function by acting on upstream p73 modulators 
or displacing inhibitory p73 interactors. A better understanding of how the p73 pathway works is mandatory to discover additional play-
ers intervening in this pathway and has important implications for the improvement of cancer treatment with the development of new 
molecules or with the reposition of currently available drugs. 
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INTRODUCTION 
  In the past 30 years, an impressive amount of clinical and basic 
research has focused on the p53 tumor suppressor protein, mainly 
because its inactivation occurs in more than 50% of all cancers [1]. 
Evidences demonstrate that p53 functions as a central node in a 
signaling pathway that prevents cancer onset and development, by 
sensing a variety of potentially oncogenic cytotoxic and genotoxic 
stress signals, and translating them into tumor-suppressive cellular 
responses such as cell-cycle arrest and apoptosis [2-5]. 
  In mammals, p53 belongs to a small gene family that includes 
two additional paralogs, p73 and p63. They are structurally and 
functionally similar to p53, and have important functions in embry-
onic development and differentiation [6-8]. Importantly, p73 and 
p63 are also involved in tumor suppression, so the entire p53 family 
can be regarded as a signaling “network” controlling cell prolifera-
tion, differentiation and death [9]. In fact, many of the signaling 
pathways that convey stress signals on p53 are also active on the 
other family members and p73 and p63 can induce cell cycle arrest 
and apoptosis in response to DNA damage and other conditions that 
activate p53. It is conceivable that a degree of functional redun-
dancy in the p53-family network provides robustness to the path-
way, to guarantee efficient responses to stress under a wide spec-
trum of conditions.  
  From a molecular point of view, p53 is a transcription factor 
and its activation/inactivation in response to stress depends on a 
complex repertoire of post-translational modifications and interac-
tions with regulatory cofactors (reviewed in [2, 3]). Notably, many 
of the post-translational modifications that regulate p53 are also 
found in p73 and p63 and several p53 modulators and binding part-
ners also interact and convey signals on p73 and p63 [9].  
  In this review we focus our attention on p73 (for regulation and 
function of p63, the reader can refer to several recent reviews [10-
13]), since many evidences indicate that p73 is a major determinant 
of chemosensitivity in human tumors [14]. 
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  It is now established that pharmacological manipulation aimed 
at restoring the levels/functions of the p53 protein can induce tumor 
regression in vivo [15-18]. Considering that p73 is rarely mutated in 
cancer, pharmacological activation of the tumor-suppressive activi-
ties of p73 represents an attractive alternative strategy to treat can-
cer cells, in particular those where p53 is lost or mutated. 
  The biology of p73 is complex since the p73 gene can be tran-
scribed in a variety of different isoforms (Fig. 1) and the resulting 
proteins have antagonistic properties since the TA-p73 isoforms 
behave as tumor-suppressors, while N-p73 isoforms have the fea-
tures of proto-oncogenes. Efficient pharmacological intervention on 
p73 must deal with this complexity. For instance, p73-activating 
drugs might be effective only in case of cancer cells expressing the 
“right” isoforms of p73 (i.e. TA-p73) and in designing new strate-
gies it would be important to develop specific drugs, or RNA-based 
therapeutics, that can modulate the relative expression of N-p73 
and TA-p73 isoforms. 
  Within this conceptual framework, we provide a broad over-
view of the p73 pathway and its regulation, and describe current 
pharmacological approaches that may be targeting this pathway in 
cancer. 
MOLECULAR STRUCTURE OF p73 
  The p73 protein has a domain organization similar to p53 (and 
p63): full length p73 (TA-p73) contains a N-terminal transactiva-
tion domain (TAD), followed by a proline-rich sequence (PR), a 
central DNA-binding domain (DBD), and a C-terminal oligomeri-
zation domain (OD), involved in formation of tetramers (Fig. 1). 
All p53 family proteins share a degree of sequence homology, in 
particular in the DBD (70% of sequence identity) [19]. The high 
similarity within the DBD confers to p73 (and p63) the ability to 
recognize and regulate many p53 target genes (e.g. p21, PUMA, 
NOXA, BAX and MDM2) in several experimental models [14, 20, 
21], although it remains an open question to what extent p53-related 
proteins regulate the same genes in physiological conditions. On the 
contrary, oligomerization domains are less conserved and p73 can 
hetero-oligomerize with p63, but not with p53 [22]. 
  A common feature of the p53 family members is that they can 
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of an internal promoter (P2), the alternative splicing of the first 
exons or the use of an alternative translation start site, generate 
several variants with a truncated N-terminus, identified collectively 
as N-p73 [19, 23]. Np73 isoforms lack a functional transactiva-
tion domain and acquire dominant negative, anti-apoptotic and pro-
proliferative functions over TA-p73 (see below). The C-terminus of 
the alpha isoforms contains a sterile alpha motif (SAM), and a ter-
minal transcription inhibitory domain, not conserved in p53 [19, 20, 
24]. Alternative splicing of the C-terminus gives rise to numerous 
additional shorter isoforms (, , , and the less investigated ,  
and ), whose specific functions are still poorly characterized [7, 
14, 25, 26] (Fig. 1). 
ROLE OF p73 IN CANCER: LESSONS FROM ANIMAL 
MODELS 
  Several evidences from in vitro studies indicate that p73 has a 
tumor suppressive role. In fact, p73 can trigger cell cycle arrest, 
cellular senescence and apoptosis upon DNA damage, by promot-
ing the transcription of many p53 target genes [21, 27]. Its knock-
down enhances the transforming potential of p53
-/- mouse embry-
onic fibroblasts infected with the oncogenic form of Ras (Ras
V12) 
[28]. Moreover, the P1 promoter, which drives the expression of 
TA-p73 isoforms, was found hypermethylated in primary lym-
phoblastic leukemias and Burkitt’s lymphomas, resulting in reduced 
TA-p73 expression [29, 30]. However, due to contradictory obser-
vations, it took several years to definitely accept TA-p73 as a tumor 
suppressor [31]. Indeed, first of all, there are no evidences that 
TP73 gene deletion is causally associated to cancer [7, 32], and 
only a very small percentage of human tumors (less than 1%) bear 
p73 mutations [33, 34]. Second, the phenotype of p73
-/- mice (gen-
erated by deleting the exons encoding the DBD, thus affecting all 
p73 isoforms) offered no evidence for p73 role in cancer; p73-null 
mice had neurological (hydrocephalus), pheromonal, reproductive, 
inflammatory and behavioral defects, but showed no increased sus-
ceptibility to spontaneous tumorigenesis, since they die 4-6 weeks 
after birth [23]. 
  Despite these characteristics, crucial evidences derived from the 
investigation of the long-term effects of p73 heterozygous mutation 
in mice, alone or with p53. It was shown that both the p73
+/- and the 
p73
+/-:p53




+/- animals [35], thus indicating 
that p73 plays an important role in preventing cancer progression in 
specific tissues. Importantly, tumors developed in p73
+/- mice reca-
pitulated human cancers (e.g. mammary adenocarcinomas) in which 
loss or reduced expression of p73 was previously reported [36-38].  
  Finally, generation of knockout mice selectively lacking the 
TA-p73 (TA-p73
-/- mice), but retaining normal expression of N-
p73 isoforms, provided evidences of the key role of TA-p73 in 
tumor suppression [39]. Compared to p73
-/- (generated by deleting 
the exons encoding the DBD, thus affecting all p73 isoforms) [23], 
these mice showed less severe hyppocampal dysgenesis, but in-
creased infertility and notably a high incidence of spontaneous tu-
mors, in particular lung adenocarcinomas. At the molecular level, it 
was demonstrated that TA-p73 binds to and regulates the functions 
of Bub1 and BubR1, suggesting a direct involvement in the Spindle 
Assembly Checkpoint (SAC), crucial for preventing aneuploidy and 
genomic instability [40]. The differences between p73
-/- and TA-
p73
-/- mice not only proved the involvement of TA-p73 in tumor 
suppression, but indirectly pointed out the oncogenic potential car-
ried by N-p73 isoforms, thus highlighting the importance of a 
proper balance between TA- and N-isoforms to maintain genomic 
fidelity in proliferating cells (see below). 
OPPOSING FUNCTIONS FOR THE SAME GENE: N-p73 
ACTS AS A PROTO-ONCOGENE 
 Many  in vitro and in vivo evidences demonstrate that the N-
terminally truncated N-p73 isoforms have an oncogenic role. In 
fact N-p73 is overexpressed in several tumors, among them breast 
[41], ovary [42, 43], prostate cancers [44], melanoma [45], neuro-
blastoma [46] and hepatocellular carcinoma [47, 48] and in most 










Fig. (1). Structure of the p73 gene and encoded proteins. 
A. Structure of the p73 gene. The TP73 gene is located on chromosome 1p36.32, and is composed of 14 principal exons. Primary transcripts generated from 
two alternative promoters (P1 and P2) undergo differential splicing to generate multiple isoforms. 
B. Overview of the principal proteins encoded by the TP73 gene. Similar to all p53-family members, p73 contains a N-terminal transactivation domain (TAD), 
a proline-rich region (PR), a central DNA-binding domain (DBD) and a C-terminal oligomerization domain (OD). In p73 there is an additional C-terminal 
sterile-alpha motif (SAM), that is present also in p63 but not in p53. Transcripts generated from the P1 promoter encode proteins with a complete TAD, that 
are transcriptionally proficient; transcripts generated from the P2 promoter encode proteins that lack the TAD and are transcriptionally inactive (N isoforms). 
Additional N-terminal truncated variants are generated by splicing of the first 2 exons. Independently from promoter usage, all transcripts can undergo alterna-
tive splicing of the C-terminal exons, thus generating a combinatorial variety of isoforms (obtainable adjoining each N-terminal variant with any of the C-
terminal variants). Only the full-length C-terminal variants ( isoforms) contain the SAM domain. For simplicity, only the principal C-terminal variants are 
represented in panel B. 
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chemoresistance, lymph node metastasis, and vascular invasion 
[49]. Transformation assays from in vitro and in vivo studies con-
firmed that enforced expression of N-p73 in fibroblasts increases 
their colony formation capacity [50] and cooperates with RAS, c-
myc and E1A in promoting transformation and tumorigenicity [51, 
52]. 
  The first demonstration that N-p73 is a bona fide oncogene 
came from the phenotype of transgenic mice in which N-p73 (in 
particular ex2/3-p73) was overexpressed in the liver under the 
control of the albumin promoter [53]. Indeed, transgenic mice dis-
played increased proliferation of hepatocytes, with acinar disor-
ganization and the appearance of pre-neoplastic nodules (adeno-
mas) that in the 83% of cases evolved in hepatic carcinoma (HCC) 
[53]. Accordingly, previous reports indicated N-p73 overexpres-
sion in HCC patients with reduced survival [48]. 
  In vitro experiments further demonstrated that the oncogenic 
potential of N-p73 isoforms lies in their ability to block concomi-
tantly three of the major onco-suppressive pathways – the RB, the 
p53, and the TA-p73 pathways – and to promote expression of anti-
apoptotic genes [41, 54-57]. Indeed, N-p73 promotes the inhibi-
tory RB hyperphosphorylation by cyclin E-Cdk2 and cyclin D-
Cdk4/6 kinases, thus boosting cell cycle progression caused by E2F 
deregulation [53, 55, 58]. Moreover, N-p73 has a dominant-
negative effect on both p53 and TA-p73, by competing for binding 
to the same target promoters and by forming transcriptionally inef-
fective heterocomplexes with them through the oligomerization 
domain [59]. Finally, at least some C-terminal variants of N-p73 
can modulate the expression of several anti-apoptotic genes inde-
pendently of p53, thus providing a further mechanisms by which 
N-p73 can exert proto-oncogenic functions [56, 57, 60, 61]. 
  Altogether these data established that the expression levels of 
N-p73 and the ratio of N to TA-p73 isoforms are crucial parame-
ters to determine the net effect of p73 and to predict the effective-
ness of chemotherapy [14, 62-64]. For this reason, factors that can 
perturb their relative levels are functionally relevant. For instance 
the overexpression of the oncogenic form of H-Ras (H-Ras
V12) in 
primary fibroblasts triggers the down-regulation of TA-p73 expres-
sion and favors the increase of N-p73 isoform. The unbalanced 
TA-/N-p73 ratio overcomes TA-p73 tumor suppressor functions, 
thereby promoting anchorage independent cell growth [65].  
  Finally, it is worth to mention that both p53 and TA-p73 bind 
the internal P2 promoter of TP73, thus promoting transcription of 
the N-p73 isoforms [54, 66, 67]. These data imply the existence of 
a negative feedback loop between N-p73 and p53/TA-p73 that 
may self-restrict their transcriptional activities. 
REGULATION OF THE p73 PATHWAY 
  Similar to p53, p73 is embedded in a complex regulatory path-
way that allows to tightly control and finely tune its activation and 
functions. Due to the relevant role that p73 (both TA- and N) 
plays in tumorigenesis, the dissection of the p73 pathway and the 
knowledge of the interconnections between its components, is fun-
damental to conceive new therapeutic approaches. We have col-
lected here some examples proving that it is theoretically and prac-
tically possible to empower either TA-p73, or block N-p73, by 
targeting/displacing proteins and enzymes involved in their regula-
tion. To better contextualize these examples, it is useful to review 
the principal mechanisms of p73 regulation. 
MODULATION OF p73 TRANSCRIPTION 
  A number of studies have investigated the transcription of TA-
p73 isoforms driven by the P1 promoter, while the regulation of the 
P2 promoter is much less clear [54, 66, 67]. 
  One important transcription factor involved in the expression of 
TA-p73 isoforms is E2F1, which can induce apoptosis, at least in 
part, by binding to its target sequences in the P1 promoter. [68-70]. 
A repertoire of post-translational modifications of E2F1 modulate 
its activity on the P1 promoter. In fact after genotoxic stress, phos-
phorylation by Chk1/2 kinases [71] and acetylation by histone ace-
tyltransferase PCAF have been shown to modify E2F1 and to trig-
ger trascription of TA-p73 [72, 73], while E2F1 deacetylation by 
Sirt1 leads to inhibition of TA-p73 transcription [74]. Also methy-
lation/demethylation of E2F1 by Set9 and LSD1 enzymes respec-
tively have been demonstrated to be critical for E2F1-dependent 
regulation of TA-p73 and induction of apoptosis [75]. 
  The activity of E2F1 on transcription of TA-p73 is also depend-
ent on other factors that bind to the P1 promoter. For instance, the 
transcriptional repressor C-EBP inhibits [76] while the Ying Yang 
1 (YY1) transcriptional activator promotes p73 expression [77].  
 The  transcriptional  repressor  EF1/ZEB was reported to bind to 
a regulatory region in the first intron of p73, exerting a silencer 
activity on E2F1-dependent transcription of TA-p73 [78].  
  Also c-myc and the viral oncogene E1A were described to 
cause the up-regulation of p73 levels and to trigger p73-dependent 
apoptosis in vitro, suggesting that, similarly to p53, p73 might be 
involved in a tumor suppressor circuitry that responds to restrict 
aberrant oncogenic signals in vivo, as recently demonstrated in the 
case of c-Myc-driven lymphomagenesis [79-81].  
REGULATION OF p73 PROTEIN LEVELS 
  An important regulator of p73 stability is the NEDD4-like 
ubiquitin ligase Itch, that recognizes a PY motif (the PPxY amino-
acid sequence) in the C-terminal region of p73 that is not present in 
p53. Upon interaction, Itch triggers p73 poly-ubiquitination and 
proteasomal degradation [82]. DNA damage causes down-
regulation of Itch through a poorly understood mechanism, thus 
allowing the stabilization and activation of p73 [82-85].  
  The interaction between Itch and p73 can be regulated by pro-
teins that indirectly affect p73 levels and activity. One example is 
provided by the transcriptional co-activator YAP1 (Yes-associated 
protein 1), a key node of the Hippo signaling pathway, active in 
controlling organ size by modulating cell polarity, proliferation, 
apoptosis, and stemness [86]. YAP1 competes with Itch for binding 
to the PY motif of p73, thus allowing its stabilization [87]. In addi-
tion, YAP1 is also a transcriptional co-factor of p73 that increases 
its transcriptional activity upon DNA damage [88-90]. 
  Mouse double minute 2 (MDM2) protein is the main E3 ubiq-
uitin ligase controlling p53 stability [91, 92]. MDM2 can also bind 
to p73, however this interaction does not trigger p73 degradation. 
Rather, MDM2 blocks p73 transcriptional activities interfering with 
its modification by the acetyl-transferase p300/CBP [93, 94]. Inter-
estingly, although MDM2 does not trigger p73 ubiquitination, it can 
catalyze p73 neddylation (the conjugation of the small ubiquitin-
like protein NEDD8 [95, 96]), which inhibits p73 transcriptional 
activity [97]. 
  Other proteins involved in p73 degradation are represented by 
the F-box protein FBXO45, that binds to and promote the ubiquiti-
nation and degradation of both TA- and N-p73 isoforms [98] and 
the U-box-type E3/E4 ubiquitin ligase UFD2a which interacts with 
the SAM domain of TA-p73, triggering its proteasomal turnover 
in a ubiquitination-independent manner [99]. Finally, NF-kB activa-
tion was also reported to impair TA-p73 functions by inducing its 
ubiquitin-dependent proteasomal degradation [100] and also by 
promoting MDM expression [101]. 
  Fewer proteins were reported to specifically promote the stabi-
lization of p73. One is NEDL2, a NEDD4-related protein that binds 
and ubiquitinates p73, surprisingly increasing its stability [102]. 
Another is the NAD(P)H quinone oxidoreductase 1 NQO1, that 
binds to p73 and prevents its ubiquitin-independent degradation by 
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  Finally, some factor might regulate differentially the protein 
levels of TA-p73 and N-p73 isoforms. One example is provided 
by c-Jun that, upon stress, prevents degradation of TA-p73 [104] 
and at the same time triggers degradation of N-p73 by the non-
classical polyamine-induced antizyme (Az) pathway. The Az an-
tizyme (a small protein initially identified as an inhibitor of ODC 
(ornithine decarboxylase), the first key enzyme in the polyamine 
biosynthesis pathway [105]), whose expression is regulated by 
polyamines during mRNA translation, binds to and accelerates the 
degradation of several substrates (e.g. ODC, Smad1, cyclinD1, and 
Aurora-A) via the proteasome. In the case of N-p73, Az expres-
sion is promoted by c-Jun upon genotoxic stress, thus leading to 
proteasome-mediated ubiquitin-independent degradation of N-p73 
[105, 106]. Recently, also the p73-Induced RING 2 protein (PIR2), 
a ring-finger domain ubiquitin ligase, was reported to regulate the 
ratio of TA- to N-p73 isoforms. Notably, PIR2 is a transcriptional 
target of TA-p73 that preferentially degrades N-p73, thus releas-
ing TA-p73 and triggering apoptosis following DNA damage [107]. 
POST-TRANSLATIONAL REGULATION OF p73: PHOS-
PHORYLATION AND ACETYLATION 
  A complex repertoire of post-translational modifications and 
protein-protein interactions control the levels and functions of all 
the members of the p53 family [9]. Besides ubiquitination and ned-
dylation (see above), p73 is regulated by phosphorylation and ace-
tylation on multiple residues. Most of these modifications are trig-
gered by DNA damaging and chemotherapeutic drugs (e.g. cis-
platin, doxorubicin and taxol) that stimulate accumulation and acti-
vation of p73 [64, 108]. 
  One important post-translational modification of p73 is phos-
phorylation by the non-receptor tyrosine kinase c-Abl that targets 
multiple residues of TA-p73. c-Abl interacts with p73 and is re-
quired for its phosphorylation upon -radiation or cisplatin treat-
ment, contributing to TA-p73 induction and p73-dependent apop-
tosis [83-85]. Notably, c-Abl phosphorylates and stabilizes also 
N-p73 isoforms, probably favoring their anti-apoptotic roles 
[109]. 
  p73 is also controlled by kinases involved in the DNA-damage 
response (DDR [110]). Indeed, the serine-protein kinase ATM 
(Ataxia Telangiectasia Mutated) activates c-Abl [111, 112] and is 
required for p73 phosphorylation upon ionizing radiation [85]. Also 
the checkpoint kinase Chk2, a downstream effector of ATM, can 
phosphorylate p73, increasing its transactivation activity and pro-
apoptotic functions [113]. Notably, ATM may modulate p73 levels 
through an additional mechanism: after cisplatin treatment ATM 
phosphorylates IKK-, one of the two catalytic subunits of the I 
kappa B kinase (IKK) complex, that accumulates in the nucleus and 
promotes p73 stabilization, thus inducing p73-dependent apoptosis 
[114, 115]. 
  Genotoxic stress activates other two pathways, the p38 MAPK 
and the JNK pathways, that mediate p73 activation. In tissue cul-
ture, JNK-mediated phosphorylation of TA-p73 increases p73 tran-
scriptional activity and stimulates induction of apoptosis after cis-
platin treatment [116]. Similarly, p38 phosphorylates threonine 
residues of p73 and this event is fundamental to mediate p73 activa-
tion by c-Abl [117]. These phosphorylations are critical for recruit-
ing the prolyl isomerase Pin. This enzyme catalyzes the conforma-
tional changes of TA-p73 required to its accumulation and acetyla-
tion [118, 119] and to direct p73 to its target promoters after drug 
treatment [118]. These conformational changes could also modulate 
the interaction of p73 with elements of chromatin remodeling com-
plexes, such as the bromodomain-containing 7 BRD7 that binds and 
regulates all p53 family members ([120, 121] and GDS unpublished 
observations). 
  Finally, the protein kinase C  (PKC), which is involved in 
DNA damage induced apoptosis, can also phosphorylate TA-p73 
at serine 289, mediating its stabilization and activation [122]. 
REGULATION OF p73 BY PROTEIN-PROTEIN INTERAC-
TIONS 
  Besides post-translational modifications, interaction with other 
proteins can deeply affect p73 functions. One example is the asso-
ciation with the ASPP (Ankirin repeats, SH3 domain, proline-rich 
protein) proteins, cofactors that can bind p73 as well as p53 and p63 
[123-125]. Association with ASPP proteins differentially affects 
p73 functions: in particular, ASPP1/2 stimulate p73 transcriptional 
activity, while iASPP inhibits p73 activation and p73-mediated 
apoptosis [125, 126]. 
  A further important level of regulation is provided by the inter-
action of p73 with other two members of the p53 family, in particu-
lar the “dominant negative” N-p63 isoforms and the oncogenic 
tumor-derived mutant forms of p53 (mut-p53). N-p63 behaves 
similarly to N-p73: it can associate with TA-p73, forming inactive 
hetero-oligomers, thus competing for binding sites on promoters 
and inhibiting TA-p73 transcriptional activity and p73-induced 
dependent apoptosis [127]. Apparently, this proto-oncogenic func-
tion of N-p63 is particularly relevant in head and neck squamous 
cell carcinomas (HNSCC), where N-p63 expression correlates 
with chemo- and radio-resistance. Accordingly, experimental 
knockdown of endogenous p63 in HNSCC cells by RNA interfer-
ence resulted in induction of TA-p73-dependent apoptosis [127]. 
This inhibitory association was detected also in cell lines derived 
from triple negative breast cancers (TNBC, lacking estrogen and 
progesterone receptors and Her2 amplification), where treatment 
with cisplatin can activate the c-Abl/TA-p73 axis and induce apop-
tosis. This outcome requires the dissociation of TA-p73 from N-
p63, that normally promotes the survival of breast cancer cells by 
inhibiting TA-p73 functions [62]. It follows that N-p63 levels may 
be crucial in determining TNBC sensitivity to cisplatin. 
  Finally, one of the most relevant inhibitory interactions of p73 
is the formation of complexes with mutant p53. In fact, in almost 
half of all tumors p53 bears point mutations that impair its tran-
scriptional activity [1]. Besides the loss of wt-p53 functions, these 
mutants acquire new oncogenic properties (“gain of function”, 
GOF) that actively sustain tumor development and progression [1]. 
One of the mechanism by which mut-p53 exerts its GOF is the 
ability to bind and inhibit p73 and p63, blocking transactivation of 
downstream targets involved in the induction of apoptosis and cell-
cycle arrest [128-134]. An important modifier of the GOF of mut-
p53 is the presence of a polymorphic site at codon 72, that encodes 
either an arginine (72R) or a proline (72P) [128, 135, 136]. While 
wt-p53 72R can induce apoptosis much better compared to the 
more frequent 72P variant [136], mut-p53 72R confers higher 
chemoresistance to cancer cells than mut-p53 72P [128, 135, 137]. 
Notably, mut-p53 72R isoforms interact with p73 and impair p73-
dependent transcription more efficiently than 72P mutants [128]. 
This difference may have relevant implications for the potential 
p73-dependent chemotherapeutic responses of cancers bearing mut-
p53. 
p73 AS A NOVEL TARGET FOR ANTICANCER THERA-
PIES 
  Substantial evidence indicates that p73 has tumor-suppressive 
functions and can vicariate, under some conditions, the antionco-
genic functions of p53 in p53-null or mut-p53 expressing cells. 
Therefore, proper stimulation of TA-p73 expression and function in 
cancer cells is a promising objective for pharmacological interven-
tion. In principle, considering that E2F1 triggers TA-p73 transcrip-
tion and E2F1 responds to genotoxic stress [161], most conven-
tional chemotherapeutic drugs can be expected to potentially acti-
vate the E2F1-TA-p73 axis, and thus increase the levels of TA-p73. 
Nonetheless, not surprisingly, TA-p73 activities are frequently 
dampened in tumors by mutation or deregulated expression of p73 
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  Taking into account the biology of p73 in cancer cells, this 
pathway can be activated by three broad categories of drugs: 1) 
compounds that can increase TA-p73 levels, for instance by stimu-
lating its transcription or by inhibiting degradation of the protein, 2) 
drugs that can modulate the expression or functions of TA-p73 
upstream regulators, for instance kinases and acetylases, and 3) 
molecules that can displace/disentangle p73 from inhibitory interac-
tions with other cellular proteins, most notably N-p73 isoforms 
and mutant p53. 
ACTIVATION OF p73 BY UNCOUPLING OF NEGATIVE 
REGULATORS 
  An intensive field of research is focusing on the identification 
of compounds able to inhibit/displace the interaction between p73 
and p53 mutants; targeting this mechanism is particularly attractive 
since it is a distinguishing feature of transformed cancerous cells 
[162].  
 RETRA.  One such compound is the small-molecule RETRA 
(REactivation of Transcriptional Reporter Activity) [138]. This 
compound promotes the expression of a set of p53-regulated genes 
in mutant p53 expressing cells, thus leading to the suppression of 
cell growth both in vitro and in mouse xenografts. Importantly, this 
activity is dependent on expression of mut-p53 and p73: in fact, 
RETRA effects were ascribed to its ability to release p73 from the 
inhibition exerted by mut-p53 and to promote an increase in p73 
levels. Considering that RETRA administration was well tolerated 
in mice, this molecule represents a promising compound to reacti-
vate p73 function in tumors [138]. 
 PRIMA-1. Additional compounds able to release p73 from the 
inhibitory binding of mut-p53, are the low molecular weight com-
pounds PRIMA-1 (p53 Reactivation and Induction of Massive 
Apoptosis), and its analog PRIMA-1
MET (APR-246, already tested 
in the clinical trial NCT00900614) [141, 163]. PRIMA-1 was 
shown to reactivate wild-type p53 (wt-p53) functions through cova-
lent binding to the core domain of p53 mutants, thus restoring their 
DNA binding activity and inducing apoptosis in tumor cells [141, 
163]. The restoration of wt-p53 conformation promoted by PRIMA-
1 allowed to speculate that PRIMA-1 could also release p73 from 
the inhibitory binding of mut-p53. In line with this hypothesis, 
PRIMA-1 was reported to cooperate with the chemotherapeutic 
drug cisplatin (that stimulates p73 functions) in inducing tumor cell 
apoptosis and inhibiting tumor growth in xenografts [142]. 
  Small Peptides. In addition to chemical compounds, alternative 
approaches aimed at identifying small peptides capable to enhance 
p73 tumor suppressive functions by releasing p73 from the inhibi-
tory association with mut-p53 or iASPP. For instance, Small Inter-
fering Mutant p53 Peptides (SIMP) derived from the core domain 
of p73 can indeed target the mut-p53/p73 complex, thus restoring 
p73 transcriptional functions and enhancing the apoptotic response 
to doxorubicin and cisplatin in transformed cells bearing mutant 
p53 [140]. Similarly, we have identified small peptide aptamers 
[139] that specifically bind to mutant p53 and trigger apoptosis only 
in mut-p53 expressing cells [139]. Further studies are required to 
verify whether the release of TA-p73 from inhibitory association 
with mut-p53 contributes to their effect [139]. 
  An approach using small peptides has also been successfully 
employed to release p73 from the inhibitory association with the 
ASPP family member iASPP. More specifically, a hybrid peptide of 
37 aminoacids (“37aa peptide”) corresponding to residues 118–142 
and 171–181 of human p53, works as an effective inhibitor of p73 
binding by iASPP [126]. Indeed, this peptide induces apoptosis 
selectively in cancer cells (and not in normal cells) by interacting 
with iASPP and restoring p73 functions [126]. Importantly, in mice, 
systemic in vivo delivery of a transgene expressing this peptide can 
trigger p73-dependent tumor regression, thus confirming that it is 
possible to specifically activate tumor suppressor functions of TA-
p73 in vivo by uncoupling the inhibitory action of iASPP [126]. 
  Nutlin-3. As already mentioned above, one important negative 
regulator of p73 functions is MDM2. The small molecule Nutlin-3 
is a powerful inhibitor of MDM2 that blocks its interaction with 
p53, thus allowing p53 stabilization and p53-dependent cell cycle 
arrest and apoptosis [143]. Notably, Nutlin-3 treatment can also 
block proliferation and induce apoptosis in cells lacking p53, or 
expressing mutant p53 [144, 145], suggesting that p53-independent 
effects of Nutlin-3 may be mediated by p73. Taking into considera-
tion that both p53 and p73 interact with the same hydrophobic 
pocket of MDM2, it is possible that Nutlin-3 could prevent forma-
tion of MDM2/p73 complexes [164]. Indeed, it was reported that 
Nutlin-3 effectively displaces MDM2 from p73 and, unexpectedly, 
causes TA-p73 accumulation in p53 null cells, thus triggering TA-
p73-dependent transcription of classical p53 targets (e.g. Noxa) 
involved in the induction of apoptosis [164]. Moreover, functional 
cooperation between Nutlin-3 and doxorubicin, a commonly used 
chemotherapeutic drug, was observed in highly chemoresistant, 
p53-null LA155N neuroblastoma cells [145]. Mechanistically, Nut-
lin-3 acts by releasing the E2F1/p73 complex from inhibitory 
MDM2 binding, while doxorubicin promotes phosphorylation of 
E2F1 by Chk1/Chk2 kinases, thus stabilizing E2F1 and promoting 
E2F1-mediated TA-p73 transcription and activation (see above). 
Altogether, these data suggest that p53-null tumors that retain the 
expression of TA-p73, will respond to the concomitant treatment 
with Nutlin-3 and DNA damaging agents [145]. 
  Panobinostat. Despite increasing knowledge on the mecha-
nisms regulating p73 stability and degradation, compounds that 
inhibit p73-specific ubiquitin ligases have not been identified so far. 
Nevertheless, modulating the levels or activities of ubiquitin-ligases 
would be highly relevant to control the amount of p73 in a cell. A 
striking example is provided by the action of a micro-RNA 
(miRNA), miR-106b, whose expression correlates with stabilization 
and activation of p73 in chronic lymphocytic leukemia (CLL) 
[148]. miRNAs are small non coding RNAs that finely regulate 
gene expression by binding the 3’UTR of their target mRNAs, thus 
reducing their translation, stability and/or changing their localiza-
tion [165]. miR-106b interacts with the 3’UTR of Itch mRNA, and 
is a negative regulator of Itch protein levels. Interestingly, Panobi-
nostat (LBH589), a pan deacetylase inhibitor tested in several clini-
cal trials, stimulates the E2F1- and myc-mediated transcription of 
miR-106b. As a consequence, by indirectly modulating the transla-
tion of Itch, Panobinostat promotes the stabilization and activation 
of p73 that, in turn, induces PUMA expression and apoptosis in 
CLL cells [148]. 
ALTERATION OF THE TA- p73 N-p73 RATIO 
  As already mentioned, inhibition of TA-p73 functions is fre-
quently observed in cancer as a consequence of N-p73 overex-
pression (see above). For this reason, selective pharmacological 
modulation of N-p73 levels may represent a valid approach to 
promote TA-p73 functions. A number of small molecules appear to 
be able to modulate the ration between TA- and N-p73, often via 
poorly understood mechanisms. 
 Celecoxib.  In this regard, the cyclooxygenase inhibitor Cele-
coxib was reported to reduce expression of N-p73 isoforms in 
primary and immortalized neuroblastoma cell lines [166]. Appar-
ently, low doses of Celecoxib negatively affect E2F1, at least in 
part through inhibition of COX2. Reduced E2F1-dependent transac-
tivation of the p73 promoter down-regulates expression of N-p73 
and TA-p73, but increased TA-p73 protein levels. The mecha-
nism behind the unexpected effect of Celecoxib on selected p73 
isoforms is still unknown. However, the increased amount of TA-
p73 and the concomitant down-regulation of N-p73, are suffi-
cient to promote drug-dependent growth arrest and apoptosis in 
treated cells [166]. These results support the potential efficacy of 
combinations of cyclooxygenase inhibitors with chemotherapy in 
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clinical trial NCT00346801, aimed at testing the efficacy of com-
bined treatment with Celecoxib and cisplatin in non-small cell lung 
cancer). 
 Arsenic  Trioxide  and  MEK1  Inhibitors. The altered balance 
between N- and TA-p73 isoforms has been shown to be important 
also in acute promyelocytic leukemia (APL). APL is characterized 
by the t(15;17)(q22;q12) translocation, that generates the oncogenic 
PML-RAR chimeric protein [167]. Treatment with arsenic triox-
ide (ATO) causes both apoptosis and differentiation of APL cells 
and, in combination with retinoic acid, ATO definitively cures most 
patients  affected by this form of leukemia [167]. Interestingly, 
treatment with ATO in combination with two MEK1 (mitogen-
activated protein kinase kinase 1) inhibitors (PD98059 and 
PD184352) greatly enhanced apoptosis of primary cells from APL 
patients, as well as immortalized APL and eritroleukemia cell lines 
[149, 150, 168]. This effect is p53-independent and relies mainly in 
the change of N-/TA-p73 ratio. Indeed, while ATO treatment 
alone stimulates the expression of both TA- and N-p73 isoforms, 
the co-administration of MEK1 inhibitors results – by an unknown 
mechanism – in preferential induction of TA-p73, thus increasing 
p73-dependent apoptosis both in vivo and in vitro [149, 150].  
  N-p73 Antisense Oligonucleotides. An alternative, RNA-based 
strategy aimed at targeting all N-p73 isoforms seems to be very 
promising [169]. By coupling locked nucleic acid (LNA) antisense 
oligonucleotide gapmers to magnetic nano-bead polyethyleneimine 
(MNB/PEI) carriers, antisense oligonucleotides selectively target-
ing N-p73 transcripts could be efficiently delivered to tumor cells 
both in vitro and in vivo. These molecules induce the selective deg-
radation of N-p73 mRNA variants; down-regulation of aberrantly 
expressed N-p73 isoforms in neoplastic cells as well in rapidly 
growing tumor xenografts resulted in inhibition of tumor growth 
and sensitization to chemotherapy, supporting the further develop-
ment of N-p73 inhibitors as potentially new anticancer agents 
[169]. 
OTHER MOLECULES THAT DIRECTLY OR INDIRECTLY 
PROMOTE p73 EXPRESSION AND FUNCTIONS 
  In the last years, several other molecules were demonstrated to 
increase p73 expression and stimulate its functions, mainly by act-
ing on the upstream signaling converging on key p73 regulators. 
Although their mechanism of action is often unclear, it is important 
to consider that most of these compounds are already in use for the 
therapy of cancer, or are under investigation in clinical trials. 
 Forodesine. Chronic lymphocytic leukemia often presents dele-
tions of TP53 and ATM that are associated with poor overall sur-
vival, shorter time to disease progression and resistance to treat-
ment [170]. Forodesine (also known as Immucillin H) is an inhibi-
tor of the purine nucleoside phosphorylase and is already employed 
in several clinical trials. Interestingly, forodesine was reported to 
have antileukemic activity in primary cells from CLL patients, 
when administered alone or in combination with other chemothera-
peutic drugs, regardless of p53 and ATM status [146, 171]. 
Forodesine effects may be at least in part mediated by p73, since 
treated cells have increased levels of the pro-apoptotic proteins TA-
p73 and Bim. Indeed, through an unknown mechanism, forodesine 
increases the transcription of TA-p73 in CLL cells, thereby promot-
ing its accumulation and functions [146]. 
  Lenalidomide. Lenalidomide (also known as CC-5013, or Rev-
limid) is an immune-modulatory agent that is giving promising 
results in several clinical trials for CLL [172, 173]. In CLL cells, 
lenalidomide stimulates transcription of CD154 (the CD40-ligand) 
via the NFATc1 (Nuclear Factor of Activated T cells c1)/NF-kB 
complex, and promotes stabilization of CD154 mRNA via the 
phosphoinositide-3 (PI3)-kinase pathway [147]. Through a poorly 
understood mechanism, increased levels of CD154 trigger c-Abl 
dependent activation of p73 expression, that, together with in-
creased levels of pro-apoptotic BID and DR5 proteins, sensitizes 
p53-deficient CLL cells to apoptosis induced by ﬂudarabine, or 
mediated by CD95 [174]. 
 Enzastaurin. As already mentioned, regulation of p73 functions 
by c-jun represents a further mechanism to control p73 activity in 
cancer cells. In this regard, an interesting molecule is Enzastaurin 
(LY317615.HCL), a small inhibitor of protein kinase C (PKC) that 
gave promising results in preclinical studies in several tumor cells 
[175]. More specifically, studies in multiple myeloma (MM) cells 
revealed that Enzastaurin promotes the accumulation of -catenin 
by blocking phosphorylations that are required for its proteasomal 
degradation. Nuclear -catenin stimulates c-Jun-dependent induc-
tion of p73 (see above) that, in turn, triggers apoptosis [153]. En-
zastaurin is currently being tested in a clinical trial for multiple 
myeloma (NCT00718419). 
 Thymoquinone. Another compound proposed to activate the p73 
pathway is the anti-neoplastic drug thymoquinone (TQ), a potent 
cytotoxic and genotoxic drug effective in several cancer cells [176]. 
TQ has been reported to generate intracellular ROS, thereby induc-
ing DNA damage and apoptosis in Jurkat cells (acute lymphoblastic 
leukemia cell line). These effects are caused by the increased ex-
pression of p73 and activation of the p73 pathway that causes also 
the down-regulation of the anti-apoptotic and epigenetic integrator 
UHRF1 [151].  
 Aurora Kinase A Inhibitors. Aurora kinase A inhibitors appear 
very promising among the new classes of compounds that are un-
dergoing clinical or preclinical validation as anticancer drugs [177]. 
In particular, the MLN8054 inhibitor, currently in clinical trials, 
was shown to induce the expression of TA-p73, thus promoting 
p73 transcriptional activity and p73-dependent apoptosis in p53-
null cells [152]. Indeed, Aurora kinase A behaves as a negative 
regulator of the p73 pathway; its overexpression was shown to in-
hibit TA-p73-dependent transcription of p53/p73 downstream 
genes, while its knock-down by means of siRNA gave opposite 
results [152]. 
 Imatinib. The small molecule Imatinib (also known as Glivec or 
STI571 [178]) is a selective tyrosine-kinase inhibitor successfully 
used for the treatment of chronic myelogenous leukemia (CML). In 
particular, Imatinib inhibits the enzymatic activity of the oncogenic 
chimera BCR-ABL generated by the reciprocal translocation of 
chromosomes 9 and 22, the most common alteration observed in 
CML [178-180]. By interfering with c-Abl activity, Imatinib can 
potentially affect p73 functions both in BCR-ABL expressing cells 
and in normal cells. In CML-derived K562 cells, treatment with 
Imatinib increased the levels of phosphorylated p38, Chk2 and TA-
p73, promoted co-localization between TA-p73 and PML, and in-
duced TA-p73- and p38-dependent apoptosis [181]. On the con-
trary, other reports confirmed that Imatinib can dampen the up-
stream signaling converging on p73 activation, thus suggesting its 
use as a tool to investigate the c-Abl TA-p73 relationship in vitro 
[174, 182], as well as a useful molecule to reduce or avoid improper 
TA-p73 activation and apoptosis in vivo [183]. 
 mTOR  Inhibitors. Finally, we would like to place particular 
attention on the recent discovery of a functional connection be-
tween the mTOR signaling and the p73 pathways [154, 155], which 
is particularly relevant given the high number of inhibitors available 
for mTOR and for its upstream regulators PI3K and AKT [184, 
185]. The serine-threonine kinase mammalian target of rapamycin 
(mTOR) is deeply involved in the regulation of protein translation, 
cell growth, and metabolism and is deregulated in several patholo-
gies, such as aging, metabolic diseases and cancer [155, 185-187]. 
Recently, an innovative approach based on analysis of gene expres-
sion signatures of cells treated with bioactive molecules suggested 
that mTOR inhibitors might be positive regulators of the p73 path-
way. Indeed, RNAi mediated knockdown of mTOR, or treatment 
with various mTOR inhibitors (e.g. rapamycin [188] or metformin, 
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TA-p73 and in its transcriptional activation [154, 155]. The 
mechanism of TA-p73 stabilization after mTOR inhibition is still 
unknown, but seems to occur at the post-translational level. 
  These results point out the attractive possibility of stimulating 
p73 functions by using the already available plethora of inhibitors 
for mTOR or for its upstream regulators, administered alone or in 
combination with standard chemotherapy [184-186]. For instance, 
co-administration of rapamycin and cisplatin is effective in induc-
ing p73-dependent cell death in breast cancer basal-like cells ex-
pressing mut-p53, representing a potential useful therapeutic strat-
egy that is currently investigated in a clinical trial (NCT00930930) 
[156]. 
 Also  -Tocopherol ether-linked acetic acid (-TEA), a promis-
ing pro-apoptotic small bioactive lipid, can also evoke p73 activa-
tion/response by the inhibition of the mTOR pathway. Indeed, by 
promoting the JNK-mediated inhibition of IRS-1, an upstream regu-
lator of the PI3K/AKT/mTOR pathway, -TEA may be considered 
as an indirect potential activator of TA-p73 stabilization triggered 
by mTOR inhibition [159]. The combination of -TEA with 
doxorubicin or cisplatin was investigated in basal-like triple-
negative breast cancer, demonstrating that the two combinations act 
synergistically, enhancing apoptosis triggered by the activation of 
p73 transcriptional activity [160]. 
  Finally, also the natural compound curcumin, a molecule that is 
currently employed in several clinical trials, could impair the 
mTOR/p73 axis due to its ability to disrupt the mTOR interaction 
with its partner Raptor, thus blocking mTOR-complex activity 
[158]. Interestingly, curcumin may potentially affect p73 functions 
also through the inhibition of NF-kB (and the subsequent stabiliza-
tion of p73, see above), through the inhibition of IkB kinase and the 
subsequent phosphorylation of IkB [189]. Accordingly, it was 
recently reported that curcumin treatment triggers p73 accumulation 
and p73-dependent apoptosis in several p53-null cancer cell lines, 
but not in normal cells [157].  
CONCLUSIONS 
  Solid experimental and clinical evidences indicate that TA-p73 
isoforms can potentially vicariate p53 functions in cancer cells by 
inducing apoptosis after DNA damage. The p73 pathway is there-
fore an attractive target for cancer drug development. Considering 
that p73 is a transcription factor, it is difficult to imagine a molecule 
or compound that could directly act on it, but we have provided 
here several examples demonstrating the potential efficacy of 
pharmacological tools that can modulate levels and activities of p73 
by acting on its upstream regulators (Table 1 and Fig. 2). The evi-
dences are more than sufficient to encourage further development 
of such tools and to justify investments for the identification of 
additional drugs (new or existing) that may target known important 






























Fig. (2). The p73 pathway and its regulators. 
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Table 1.  List of Drugs Targeting the p73 Pathway 
Drug Target  Mechanism  of  Action  Effects  Reference 
RETRA  Mutant p53 
(?) 
Displacement of mut-p53/p73 complex  p73-dependent inhibition of cell growth in vitro and 
in vivo in tumor xenografts 
[138] 
Aptamers  Mutant p53  Unknown  Apoptosis in mut-p53 expressing cells  [139] 
SIMP peptides  Mutant p53  Displacement of mut-p53/p73 complex  p73-dependent apoptosis in mut-p53 expressing 






Mutant-p53  Reactivation of mutant p53 through covalent 
binding to their core domain 
Apoptosis in tumor cells expressing mutant-p53, 
alone or in combination with cisplatin 
[141, 142] 
37aa peptides  iASPP  Displacement of iASPP-p73 complex  p73-dependent apoptosis in vitro and in tumor 
xenograft in vivo 
[126] 
Nutlin-3 MDM2  Displacement of MDM2-E2F1-p73 complex  Apoptosis in p53-null or mut-p53 expressing cells in 
combination with chemotherapeutic drugs (doxoru-
bicin) 
[143-145] 
Forodesine  Unknown  Increased TA-p73 transcription  Apoptosis in CLL cells, alone or in combination 





Unknown  Induction of CD154 expression, that trigger the 
c-Abl-mediated activation of p73 
CD95-mediated or ﬂudarabine-induced c-abl/p73 




HDACs  E2F1- and myc-mediated transcription of miR-
106b, that targets the p73 ubiquitin ligase Itch 
TA-p73 induced apoptosis in CLL cells  [148] 
Arsenic trioxide 
(ATO) 
PML-RAR  Reduction of N-p73 levels and increase of 
p300-mediated acetylation of p73 in APL cell 
lines. Increased expression of both TA- and N-
p73 expression in primary APL cells. 
p73-mediated apoptosis alone, greatly increate by 





MEK1  Alteration of TA/N-p73 ratio: reduction of N-
p73 levels and the accumulation and tyrosine 
phosphorylation of TA-p73 
p73-mediated apoptosis alone in co-administration 
with ATO 
[149, 150] 
Thymoquinone  Unknown  Increased TA-p73 protein level  p73-dependent cell cycle arrest and apoptosis in 
acute lymphoblastic leukemia (ALL) Jurkat cell line 
[151] 
MLN8054  Aurora 
kinase A 





Accumulation of -catenin, that promotes c-Jun-
dependent induction of p73 
p73-dependent apoptosis in multiple myeloma cells  [153] 
Rapamycin FKB12  Direct mTOR inhibition and increased TA-p73 
levels 
p73-dependent cell death, increased by cisplatin co-
administration in basal-like triple negative breast 
cancer cells 
[154-156] 
Metformin AMPK  Increased inhibitory Ser789 phosphorylation of 
IRS-1, decreased PI3K/AKT activation, in-
creased phosphorylation of TsC2, inhibition of 
Rheb, inhibition of mTOR, increased TA-p73 
levels 
Not investigated  [155] 
Curcumin  mTOR, NF-
kB 
NF-kB and mTOR inhibition and TA-p73 accu-
mulation and activation 
p73-dependent apoptosis  [157, 158] 
-TEA Unknown  1- Increased p73 transcriptional activity, down-
stream of c-Abl, JNK and Yap.  
2- Indirect JNK-mediated inhibition of mTOR, 
increased TA-p73 levels 
p73-dependent apoptosis in basal-like triple negative 
breast cancer cells 
[159, 160] 
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  In parallel, we need to improve our knowledge of the molecular 
basis of p73 expression and regulation, aiming to a “global” or 
“system-level” comprehension of the signaling pathways that trig-
ger tumor-suppressive activities of p73 in response to DNA damage 
and other stimuli. Such knowledge will be instrumental to reach the 
following crucial objectives. 1) To develop diagnostic markers of 
the “p73 pathway status” that could predict whether a p73-
activating therapy would be appropriate in a given tumor and per-
haps to direct the choice of which upstream p73 modulator should 
be targeted by a new generation of pathway-tailored drugs. In fact, 
the efficacy of any drug aimed at modulating the p73 pathway is 
going to be affected by cell-specific parameters: for example, which 
p73 isoforms are actually expressed and at what relative levels and 
what is the status of the upstream p73 regulators that are targeted by 
the drug under consideration. 2) To suggest the potential “reposi-
tioning” [190, 191] of drugs that are already in clinical use for other 
diseases, but can directly or indirectly affect molecular components 
of the p73 signaling pathway, as strikingly exemplified by the case 
of mTOR inhibitors described above. 3) To identify additional 
components of the p73 pathway that might in general influence the 
outcome of p73-targeted therapies, and may themselves become 
molecular targets for novel drugs, or repositioning of existing com-
pounds. 
  We are confident that molecular insights derived from basic and 
clinical research integrated with next generation post-genomic tools 
and the use of gene expression signatures to discover connections 
among pathways and drugs will significantly increase – in the near 
future – the number of drugs potentially targeting the p73 pathway. 
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